Importantly, without enhancing adverse effects of paclitaxel, dapagliflozin improved the efficacy of paclitaxel to promote neuropathy, but it improved the efficacy of chemotherapy to slow tumor growth in murine breast cancer models with mutations in pathways upstream, but not downstream, of canonical insulin signaling (Fig. 7). The gene discussed is INS; the disease is breast cancer.